1 / 101

STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab]

STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab]. Oncologic Drugs Advisory Committee December 17, 2002. Proposed Indication.

hilda-haney
Download Presentation

STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab]

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. STN 125011 Tositumomab Therapeutic Regimen (TTR)[tositumomab plus I-131 tositumomab] Oncologic Drugs Advisory Committee December 17, 2002

  2. Proposed Indication Treatment of Patients with Relapsed or Refractory, Low-Grade, Follicular, or Transformed Low-Grade Non-Hodgkin’s Lymphoma (NHL) including Patients with Rituximab-Refractory Follicular NHL

  3. OVERVIEW OF CLINICAL STUDIESEfficacy • Study RIT-II-004 - The primary efficacy trial supporting the request for accelerated approval for the treatment of chemotherapy-refractory patients with low grade and follicular NHL, with or without transformation.

  4. OVERVIEW OF CLINICAL STUDIES Efficacy • Study CP97-012 : The primary efficacy trial supporting standard approval for the treatment of Rituximab-refractory patients with follicular NHL.

  5. OVERVIEW OF CLINICAL STUDIES Efficacy • Three additional studies provide supportive anti-tumor activity data for the proposed indications. • RIT-II-002 - controlled Phase 2 study • RIT-II-000 & 001 are single-arm trials

  6. Study RIT-II-004Trial Design • multicenter • historically-controlled • single-arm • patients w/ chemotherapy-refractory low grade or follicular NHL • with or without transformation

  7. Study RIT-II-004Analytic Plan (Final) • Primary Efficacy Endpoint – • proportion of patients with longer duration of response after TTR vs. proportion with longer duration of response after Last Qualifying Chemotherapy (LQC) regimen • based on MIRROR Panel assessment

  8. Study RIT-II-004 Analytic Plan (Final) • Secondary Efficacy Endpoints • overall response rate • complete response rate • duration of response • time to progression • survival

  9. Study RIT-II-004 • Study population consisted of 61 patients enrolled at 8 centers • FDA analyses include 1 patient who withdrew consent and did not receive either dosimetric or therapeutic dose

  10. RIT-II-004 Among the 61 patients registered: • 7 (11%) responded to LQC • 1 (2%) achieved CR/CCR to LQC • Median duration of response - 4.1 months (range 3.0-5.4 months)

  11. Study RIT-II-004 MIRROR-Assessed Response

  12. Study RIT-II-004Primary Endpoint Analysis • Equivalent duration • Longer duration of response after TTR (>30 days longer) than after LQC • Longer duration of response after LQC than after TTR

  13. Study RIT-II-004Primary Endpoint Analysis

  14. Study RIT-II-004Primary Endpoint Analysis Response Frequency % of 61 ---------------------------------------------------------------------- Equivalent duration 29 48% Longer response w/ TTR 27 44% Longer response w/ LQC 5 8% Significant by McNemar’s and by sign-rank test

  15. Study RIT-II-004

  16. Study CP97-012Design • Single‑arm, multicenter • Conducted in patients who had relapsed after  1 course(s) of Rituximab • Endpoints: ORR, CR+CCR, response duration, time to progression, time to treatment failure, and survival.

  17. Study CP97-012 Population/Subpopulations • Registered n = 43 • Treated n = 40 • “Indicated” Population • follicular NHL • Rituximab response duration of < 6 mosn = 30

  18. Study CP97-012 Registered (n=43)

  19. Study CP97-012 “Indicated” subpopulation (n=30)

  20. Study CP97-012Exploratory Analysis of efficacy by responsiveness to Rituximab

  21. Supportive studies • RIT-II-002 • RIT-II-001 • RIT-II-000

  22. Study RIT-II-002Design • Two-arm • Open-label • Multi-center • Randomized (not stratified) • Chemotherapy-relapsed or refractory • Low-grade, follicular, or transformed low-grade NHL

  23. Study RIT-II-002Design • Treatment Arms • Arm A –TTR (hot arm) • Arm B – unlabeled Tositumomab antibody (cold arm) • Endpoints: • 1 CR/CCR • 2° ORR, response duration, TTP, and toxicity profile

  24. Study RIT-II-002 • 78 patients enrolled • 42 in arm A • 36 in arm B • Prognostic variables similar except for • 7% intermed. histology in A vs. 17% B • 10% high IPI in Arm A vs. 3% in Arm B • 52%  5 cm lesions Arm A vs. 34% Arm B

  25. Study RIT-II-002

  26. Survival in Years RIT-II-002

  27. Study RIT-I-000 • Single-center, dose escalation study • to determine • the optimal biologic dose of cold antibody • MTD for TTR in patients with and without prior BMT • 59 patients were enrolled • 22 patients without prior BMT were treated at the MTD

  28. Study RIT-II-001 • Multicenter, single arm study to assess reproducibility of dosimetry methods across clinical sites • 47 patients enrolled

  29. Overview of Study Results

  30. Pooled Subset Analyses • Long-term responders • Submitted by sponsor to show that TTR provides “a meaningful therapeutic benefit over existing treatments” in support of accelerated approval • Low-Grade Transformed NHL • Analyses requested by FDA to assess for differences in activity in transformed vs. non-transformed since results include both types of patients

  31. Long-Term Responders • Defined as responding patients with TTP  1 year per MIRROR review • 76/271 (28%) patients identified by MIRROR • 68/271 who rec’d a single dosimetric and any therapeutic dose • Patients retrospectively identified across 5 efficacy/activity studies (n=271)

  32. Long-term responders (n=68) • CR/CCR - 54 of 68 (79%) • PR - 14 of 68 (21%) • Median response duration 4.9 years (range from 0.9 to 7.8+ years)

  33. Low Grade NHL w/Transformation • 71 of 271 (26%) patients across 5 efficacy studies with evidence of transformed histology • FDA reviewed and confirmed sufficient info to document transformation in 40 of the 59 (remaining 12 under review)

  34. Low Grade NHL w/Transformation • ORR 40% (16/40) • CR/CCR 26% (11/40) • Median response duration 1.6 years (range 0.1+ to 4.9 years)

  35. Safety Summary • Hematologic-acute • Neutropenia/lymphopenia: Infections • Thrombocytopenia: Hemorrhagic events • Infusional reactions • Gastrointestinal toxicity • Immune responses to murine protein • Delayed toxicity due to irradiation • Hypothyroidism • Secondary leukemias, myelodysplasia, other cancers

  36. Safety Database • Safety data provided for 620 patients • 229 patients enrolled in 5 efficacy/activity studies (RIT‑I‑000, RIT-II-001, RIT‑II‑002, RIT‑II‑004 and CP‑97‑012) • 391 patients treated under expanded access experience in Protocol CP-98-020 and 4 sponsor-investigator INDs

  37. Safety Database

  38. Safety Database • Safety profile in 5 efficacy/activity studies (n=229, ISS-A) showed a higher incidence for adverse events in the first 13 weeks vs. expanded access (n=391, ISS-B) • Less comprehensive collection of data in expanded access and no monitoring • Underreporting of AEs in expanded access confirmed during inspection

  39. Incidence of AEs

  40. Incidence of AEs

  41. Incidence of SAE

  42. Acute Hematologic Toxicity • Complete blood counts were to be collected at least weekly beginning at week 3 until • recovery from nadir • removal from study • Patients with missing data during the period of expected nadir (weeks 5-9) or at recovery (week 13) were assigned worst toxicity in “Worst case scenario” analyses

  43. Acute Hematologic Toxicity

  44. Acute Hematologic Toxicity

  45. Lymphopenia in RIT-001 & 003

  46. Infections/Fever Fever • 37% (84 patients) • 19% (43 pts)  study day 14 • 7-8% (15 pts/3 missing) fever associated with neutropenia

  47. Infectious Events

More Related